FTH trades 39.2% above Wall Street's consensus target of $5.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FTH achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, Faeth Therapeutics, Inc. (FTH) has a Wall Street consensus price target of $5.50, based on estimates from 6 covering analysts. With the stock currently trading at $9.04, this represents a potential downside of -39.2%. The company has a market capitalization of $234M.
Analyst price targets range from a low of $5.00 to a high of $6.00, representing a 18% spread in expectations. The median target of $5.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FTH trades at a trailing P/E of -1.1x. Analysts expect EPS to grow +66.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
IMVTImmunovant, Inc. | $6.9B | $33.21 | $40.00 | +20.4% | Buy | — | 23 |
ADCTADC Therapeutics S.A. | $172M | $1.35 | $3.50 | +159.3% | Hold | — | 12 |
IMCRImmunocore Holdings plc | $1.4B | $27.81 | $39.00 | +40.2% | Buy | — | 14 |
NKTXNkarta, Inc. | $89M | $1.25 | $9.00 | +620.0% | Buy | — | 12 |
CRVSCorvus Pharmaceuticals, Inc. | $855M | $10.17 | $27.00 | +165.5% | Buy | — | 13 |
IOVAIovance Biotherapeutics, Inc. | $3.4B | $7.53 | $13.56 | +80.1% | Buy | — | 21 |
FATEFate Therapeutics, Inc. | $119M | $1.02 | $5.63 | +452.0% | Buy | — | 31 |
AGENAgenus Inc. | $259M | $6.21 | $25.00 | +302.6% | Buy | 23.2x | 12 |
NVAXNovavax, Inc. | $1.3B | $7.96 | $18.00 | +126.1% | Buy | — | 23 |
REGNRegeneron Pharmaceuticals, Inc. | $98.7B | $957.76 | $904.60 | -5.6% | Buy | 14.1x | 49 |
Quick answers to the most common questions about buying FTH stock.
FTH's consensus price target is $5.5, -39.2% below the current price of $9.04. The 6 analysts tracking FTH see downside risk at present valuations.
FTH has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $5.5 implies -39.2% downside from current levels.
FTH's current price is $9.04 with a consensus target of $5.5 (-39.2% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for FTH, while the most conservative target is $5. The consensus of $5.5 represents the median expectation. These targets typically reflect 12-month expectations.
FTH is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FTH stock forecast based on 6 Wall Street analysts shows a consensus price target of $5.5, with estimates ranging from $5 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Analysts are cautious on FTH, with 0 Sell ratings and a price target of $5.5 (-39.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FTH analyst price targets range from $5 to $6, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.